Up next

Autoplay

Osimertinib in Advanced Non–Small-Cell Lung Cancer

2 Views • 07/04/23
Share
Embed
administrator
administrator
Subscribers
0

EGFR tyrosine kinase inhibitors are standard treatment for non small-cell lung cancer. Despite high tumor response rates, disease progresses in most patients after 9 to 13 months. Is there a way to lengthen progression-free survival? New research findings are summarized in this short video. Full study: http://nej.md/2gymJkj

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay